Does Medicare Cover Ozempic in 2026?The Honest Answer

People usually search “does Medicare cover Ozempic” right after one of three things happens: the pharmacy quoted them $625 or close to a thousand dollars and they almost fell over; their prior authorization got denied with a one-line code they don’t understand; or they turned 65, switched to Medicare, and watched their old $25 copay turn into something scarier.

Real Medicare beneficiaries posting in public forums about this exact moment:

That cap is huge. Before 2025, there was no cap, and people on expensive medications routinely paid $5,000 or more a year. The Inflation Reduction Act ended that. In 2026 the cap is $2,100. According to KFF, it rises to $2,400 in 2027.

What Ozempic is approved for (and why this matters)

Ozempic (semaglutide) has these FDA-approved uses, all tied to type 2 diabetes:

1. Improving blood sugar control in adults with type 2 diabetes
2. Reducing the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes plus known heart disease
3. Reducing the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes plus chronic kidney disease (this indication is for Ozempic injection)

That kidney indication is newer and worth knowing about. If you have type 2 diabetes and chronic kidney disease, your doctor can write Ozempic injection specifically for the kidney indication — giving the plan a second valid reason to approve coverage.

What Ozempic is NOT FDA-approved for: weight loss, prediabetes, type 1 diabetes, or insulin resistance without diabetes.

What tier Ozempic typically lands on

Most Part D plans place Ozempic on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). A few put it on Tier 5 (specialty).

• Tier 3 — usually a flat copay, often around $40–$50 a month
• Tier 4 — usually 25% coinsurance, which can mean $200+ a month until you hit your deductible and then again until you hit the $2,100 cap
• Tier 5 — 25–33% coinsurance; uncommon for Ozempic but it happens

Prior authorization: what your doctor has to send in

Most Part D plans require a prior authorization (PA) before paying for Ozempic. The PA is a short medical form your doctor’s office submits. The plan reviews it, usually within 72 hours. Here’s what makes a strong PA:

• Diagnosis code on the prescription — must be E11.x (type 2 diabetes). Not E66.x (obesity). Not Z71.3 (counseling).
• Most recent A1C result — typically within the last 3–6 months
• List of other diabetes drugs tried first — metformin is almost always expected
• A statement of medical necessity if you’re skipping step therapy
• Any related diagnoses — heart disease, kidney disease, peripheral artery disease — that give the plan additional FDA-approved reasons to say yes

If your doctor’s office uses electronic prior auth (most do in 2026), this takes 1–2 business days. If a delay would put your health at risk, your doctor can request an expedited PA, which gets a decision within 24 hours.

Step therapy: when your plan makes you try something cheaper first

Some plans require you to fail or not tolerate a less-expensive diabetes drug before approving Ozempic. The most common requirement is metformin. Some plans require a different GLP-1 like Trulicity or Rybelsus first.

If you’ve already been on these drugs and they didn’t work — write that down. Your doctor can submit a step therapy exception with documentation, and it often gets approved when the case is well-documented.

When Part D was created in 2003, Congress carved out a few categories of drugs as automatic exclusions — including anti-obesity drugs. Two decades later, the science has changed, but the statute hasn’t. The Treat and Reduce Obesity Act has been reintroduced in Congress repeatedly without passing as of May 2026.

What has changed is how CMS is working around the rule using demonstration authority under Section 402 of the Social Security Act. That’s where the GLP-1 Bridge comes from.

What happens if your doctor writes Ozempic for weight loss anyway: The pharmacy submits the claim. The plan checks whether the prescribed use is a medically accepted indication for Part D coverage. If it isn’t (and weight loss alone isn’t), the claim is denied. You either pay full retail (around $1,027.51 per month list price) or you walk away.

Some patients ask their doctor to “code it as diabetes.” Don’t. It’s insurance fraud. The right path isn’t fraud — it’s finding the program that actually fits your situation.

Prediabetes alone is not enough for Ozempic coverage. Prediabetes is not an FDA-approved indication for Ozempic. Medicare won’t cover Ozempic for prediabetes. However, prediabetes plus a BMI of 27 or higher is a qualifying condition for the Medicare GLP-1 Bridge — meaning you may qualify to get Wegovy, Zepbound KwikPen, or Foundayo for $50 a month starting July 1, 2026. Different drug, same goal, different coverage path.

Eligibility is based on BMI at the time GLP-1 therapy was initiated, plus (for some categories) a qualifying medical condition.

Path 1 — BMI 35 or higher, alone. No additional condition required.

Path 2 — BMI 30 or higher, with one of these:

• Heart failure with preserved ejection fraction
• Uncontrolled hypertension (systolic over 140 or diastolic over 90, while on two blood pressure medications)
• Chronic kidney disease, stage 3a or higher

Path 3 — BMI 27 or higher, with one of these:

• Prediabetes (per American Diabetes Association guidelines)
• A prior heart attack
• A prior stroke
• Symptomatic peripheral artery disease

Plus everyone needs all of this: Age 18+; enrolled in a Part D PDP or MA-PD coordinated care plan (HMO, HMOPOS, Local PPO, or Regional PPO) for 2026; prescription specifically for weight reduction and maintenance paired with structured nutrition and physical activity; prescriber submits the PA to the central processor (Humana’s Limited Income Newly Eligible Transition infrastructure per CMS), not to your Part D plan.

The official Ozempic Savings Card from Novo Nordisk excludes anyone on Medicare, Medicaid, VA, DoD, or TRICARE. So do the Wegovy Savings Offer and the Zepbound copay card. NovoCare also says government-insured patients may not use NovoCare Pharmacy self-pay programs even if they choose to pay outside their insurance. This isn’t a Novo Nordisk policy decision — it’s federal anti-kickback law.

Your real options instead of the savings card:

1. Extra Help / LIS — apply at SSA.gov if your income and resources qualify
2. Medicare Prescription Payment Plan (M3P) — opt in through your Part D plan to spread your annual covered Part D costs across 12 monthly payments. It does not lower your total cost — it smooths the timing.
3. Switch plans during AEP (October 15 – December 7) if a different plan covers Ozempic at a much lower tier
4. Mail-order or 90-day fills — ask your plan whether preferred mail-order pricing lowers your specific cost

If you have both Medicare and Medicaid (about 12 million Americans do), your state Medicaid program may cover what Medicare won’t. As of January 2026, KFF reports that 13 state Medicaid programs covered GLP-1 medications for obesity under fee-for-service. The list is changing quickly.

If you’re dually eligible, call your state Medicaid office directly and ask: “Does my state Medicaid cover semaglutide or tirzepatide for obesity? What’s the prior authorization process?” Don’t rely on a third-party state list — verify with your state. For Medicaid coverage details, also see our guide Does Medicaid Cover Wegovy?.

CMS has not announced a Part D BALANCE launch date after 2027. Re-check CMS guidance during 2027 Annual Enrollment if you’re planning coverage after the Bridge ends.

If BALANCE never launches for Part D, then on January 1, 2028 the strict pre-2026 rules return: Ozempic only for type 2 diabetes-related uses, Wegovy only for cardiovascular risk reduction, Zepbound only for sleep apnea (with obesity). Weight-loss-only coverage disappears unless Congress acts.

There’s a separate note worth knowing: Ozempic, Rybelsus, and Wegovy are selected drugs in the Medicare Drug Price Negotiation Program, with negotiated Maximum Fair Prices taking effect January 1, 2027. Whether your personal copay drops depends on your plan’s design.